When a Parkinson's disease patient starts to hallucinatePOEWE, Werner.Practical neurology (Print). 2008, Vol 8, Num 4, pp 238-241, issn 1474-7758, 4 p.Article

Depression in Parkinson's diseasePOEWE, Werner.Journal of neurology. Supplement. 2007, Vol 254, Num 5, pp 49-55, issn 0939-1517, 7 p.Article

Treatment of dementia with lewy bodies and Parkinson's disease dementiaPOEWE, Werner.Movement disorders. 2005, Vol 20, pp S77-S82, issn 0885-3185, SUP12Conference Paper

Treatments for Parkinson disease-past achievements and current clinical needsPOEWE, Werner.Neurology. 2009, Vol 72, Num 7, issn 0028-3878, S65-S73, SUP2Article

Prodromal Parkinson's DiseaseBERG, Daniela; POEWE, Werner.Movement disorders. 2012, Vol 27, Num 5, issn 0885-3185, 77 p.Serial Issue

Apomorphine : An underutilized therapy for Parkinson's diseasePOEWE, Werner; WENNING, Gregor K.Movement disorders. 2000, Vol 15, Num 5, pp 789-794, issn 0885-3185Article

Premotor Parkinson diseaseTOLOSA, Eduardo; POEWE, Werner.Neurology. 2009, Vol 72, Num 7, issn 0028-3878, 75 p., SUP2Serial Issue

Atypical Parkinsonian DisordersPOEWE, Werner; WENNING, Gregor K.Movement disorders. 2005, Vol 20, issn 0885-3185, 149 p., SUP12Conference Proceedings

Oxcarbazepine in glossopharyngeal neuralgia: Clinical response and effect on serum lipidsLUEF, Gerhard; POEWE, Werner.Neurology. 2004, Vol 63, Num 12, pp 2447-2448, issn 0028-3878, 2 p.Article

The role of COMT inhibition in the treatment of Parkinson's diseasePOEWE, Werner.Neurology. 2004, Vol 62, Num 1, pp S31-S38, issn 0028-3878, SUP1Article

Psychosis in Parkinson's diseasePOEWE, Werner.Movement disorders. 2003, Vol 18, Num 6, pp S80-S87, issn 0885-3185, SUPConference Paper

The need for neuroprotective therapies in Parkinson's disease : A clinical perspectivePOEWE, Werner.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S2-S9, SUP4Article

In vitro models of multiple system atrophySTEFANOVA, Nadia; REINDL, Markus; POEWE, Werner et al.Movement disorders. 2005, Vol 20, pp S53-S56, issn 0885-3185, SUP12Conference Paper

How to diagnose dementia with lewy bodies : State of the artGESER, Felix; WENNING, Gregor K; POEWE, Werner et al.Movement disorders. 2005, Vol 20, pp S11-S20, issn 0885-3185, SUP12Conference Paper

Defining At-Risk Populations for Parkinson's Disease: Lessons From Ongoing StudiesBERG, Daniela; MAREK, Ken; ROSS, George W et al.Movement disorders. 2012, Vol 27, Num 5, pp 656-665, issn 0885-3185, 10 p.Article

Therapeutic strategies in multiple system atrophyWENNING, Gregor K; GESER, Felix; POEWE, Werner et al.Movement disorders. 2005, Vol 20, pp S67-S76, issn 0885-3185, SUP12Conference Paper

Dopamine agonists in the treatment of Parkinson's disease : new developments. Satellite symposiumPOEWE, WERNER; CARACENI, TOMMASO.Neurology. 1995, Vol 45, Num 3, issn 0028-3878, 34 p., SUP3Conference Proceedings

When and how should treatment be started in Parkinson disease?LANG, Anthony E.Neurology. 2009, Vol 72, Num 7, issn 0028-3878, S39-S43, SUP2Article

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson diseaseSCHAPIRA, Anthony H. V.Neurology. 2009, Vol 72, Num 7, issn 0028-3878, S44-S50, SUP2Article

Can we achieve neuroprotection with currently available anti-parkinsonian interventions?OLANOW, C. Warren.Neurology. 2009, Vol 72, Num 7, issn 0028-3878, S59-S64, SUP2Article

Dysautonomia and Cognitive Dysfunction in Parkinson's DiseasePOEWE, Werner.Movement disorders. 2007, Vol 22, issn 0885-3185, S374-S378, SUP17Conference Paper

Parkinsonism-dementia complex of guamSTEELE, John C.Movement disorders. 2005, Vol 20, pp S99-S107, issn 0885-3185, SUP12Conference Paper

Tau gene mutations and their effectsGOEDERT, Michel.Movement disorders. 2005, Vol 20, pp S45-S52, issn 0885-3185, SUP12Conference Paper

Treatment of progressive supranuclear palsy and corticobasal degenerationLANG, Anthony E.Movement disorders. 2005, Vol 20, pp S83-S91, issn 0885-3185, SUP12Conference Paper

The Parkinson chimeraLEES, Andrew J.Neurology. 2009, Vol 72, Num 7, issn 0028-3878, S2-S11, SUP2Article